Factor Bioscience Expands Translational Science Team, Appoints Kyle Garland, Ph.D., as Director of Translational Science
Factor Bioscience Expands Translational Science Team, Appoints Kyle Garland, Ph.D., as Director of Translational Science
CAMBRIDGE, Mass., April 9, 2024 /PRNewswire/ -- Factor Bioscience Inc. ("Factor"), a Cambridge, Massachusetts-based biotechnology company developing advanced mRNA and cell-engineering technologies, today announced the addition of three members to its translational science team, which will be led by Kyle Garland, Ph.D., who joins Factor as Director of Translational Science.
马萨诸塞州剑桥，2024年4月9日 /PRNewswire/ — 总部位于马萨诸塞州剑桥的开发先进mRNA和细胞工程技术的生物技术公司Factor Bioscience Inc.（“Factor”）今天宣布，其转化科学团队将增加三名成员，该团队将由加入Factor担任转化科学总监的凯尔·加兰博士领导。
"We are excited to welcome three talented scientific professionals."
“我们很高兴欢迎三位才华横溢的科学专业人士。”
"We are excited to welcome three talented scientific professionals to Factor," said Dr. Matt Angel, Co-Founder, Chairman, and CEO of Factor. "Dr. Garland, who is joined by Associate Scientists, Raven Hinkel and Elizabeth Belcher, has deep translational research expertise in mRNA and cell engineering. The addition of Kyle and his team will enhance Factor's ability to support our strategic partners and accelerate our efforts to translate our technologies to new products."
Factor联合创始人、董事长兼首席执行官马特·安吉尔博士说：“我们很高兴欢迎三位才华横溢的科学专业人士加入Factor。”“加兰博士与助理科学家雷文·欣克尔和伊丽莎白·贝尔彻一起加入，在mRNA和细胞工程方面拥有深厚的转化研究专业知识。Kyle及其团队的加入将增强Factor支持我们的战略合作伙伴的能力，并加快我们将技术转化为新产品的努力。”
"Their collective experience spans many relevant fields of science, including synthetic mRNA, mRNA cell reprogramming, gene editing, cell manufacturing, immunoengineering, and nucleic acid formulation, among others," said Dr. Christopher Rohde, Co-Founder and Chief Technology Officer.
联合创始人兼首席技术官克里斯托弗·罗德博士说：“他们的集体经验涵盖了许多相关的科学领域，包括合成mRNA、mRNA细胞重编程、基因编辑、细胞制造、免疫工程和核酸配方等。”
Dr. Garland added, "I firmly believe that Factor's extensive portfolio of foundational mRNA and cell-engineering technologies has the potential to revolutionize many areas of biotechnology research and development. I look forward to working with Drs. Angel and Rohde to deploy these powerful technologies through the development of new products."
加兰博士补充说：“我坚信，Factor广泛的基础mRNA和细胞工程技术组合有可能彻底改变生物技术研发的许多领域。我期待与安吉尔博士和罗德博士合作，通过开发新产品来部署这些强大的技术。”
Dr. Garland joins Factor from Eterna Therapeutics, where he headed the Department of Research and Development, managing the entire portfolio of preclinical programs and overseeing all operational aspects of the company's strategic collaborations. He holds a Doctor of Philosophy degree in Chemical Engineering from Vanderbilt University and a Bachelor of Science degree in Bioengineering from Lehigh University.
加兰博士从Eterna Therapeutics加入Factor，领导研发部，管理整个临床前项目组合，并监督公司战略合作的所有运营方面。他拥有范德比尔特大学化学工程哲学博士学位和利哈伊大学生物工程理学学士学位。
About Factor Bioscience
关于因子生物科学
Factor Bioscience develops technologies for engineering cells to promote health and improve lives. For more information, visit .
Factor Bioscience开发了工程细胞的技术，以促进健康和改善生活。欲了解更多信息，请访问。
SOURCE Factor Bioscience
来源因子生物科学